Drug Trial Radar · NCT05547061
A Phase 1/2 Clinical Trial to Evaluate the Safety, Tolerability, Dosimetry, and Anti-tumor Activity of Ga-68-NGUL / Lu-177-DGUL in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Refractory to Standard Therapy
Last checked: Nov 20, 2026Latest source record: Oct 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
91
Actual
Start
Apr 12, 2021
Primary completion
Jul 30, 2025
Study completion Feb 28, 2026
Sponsor
- Lead sponsor
- Cellbion Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Sep 21, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Factorial
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 19 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This clinical trial is an open-label, single-arm, multi-center, escalation (Phase 1 Part B only), rater-blind (Phase 2 only), phase 1/2 trial to evaluate the diagnostic validity/safety of Ga-68-NGUL and efficacy/safety of Lu-177-DGUL on the anti-tumor activity that aims to simultaneously evaluate diagnostic and therapeutic validity.
Conditions
- Prostate Cancer
- mCRPC
Interventions
Lu-177-DGULDrug
Administered intravenously once every 6 weeks (1 cycle) for a maximum of 6 cycles.
Ga-68-NGULDrug
Administered intravenously during screening and every 12 weeks after the first administration of Lu-177-DGUL.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Response Rate(ORR) according to RECIST 1.1Time frame: From baseline until radiographic progression or death from any cause, whichever comes first. assessed up to 36 months
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Chonnam National University Hwasun Hospital
Hwasun, South Korea
Seoul National University Hospital
Seoul, South Korea
Asan Medical Center
Seoul, South Korea
Seoul National University Bundang Hospital
Seoul, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.